<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00747214</url>
  </required_header>
  <id_info>
    <org_study_id>CRx-102-002</org_study_id>
    <nct_id>NCT00747214</nct_id>
  </id_info>
  <brief_title>A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA</brief_title>
  <official_title>A Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus DMARD Therapy to That of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and Cytokines in Subjects With RA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zalicus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zalicus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was a Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus
      DMARD Therapy to that of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and
      Cytokines in Subjects with Rheumatoid Arthritis. This Phase II, 6-week blinded study was
      planned for 60 subjects with moderate to severe rheumatoid arthritis (RA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study was to:

      • Compare the response of CRx-102 plus DMARD therapy to placebo plus DMARD therapy in
      lowering CRP levels in rheumatoid arthritis subjects.

      The secondary objectives of this study were to:

        -  Evaluate the changes in inflammatory cytokines in subjects treated with CRx-102 plus
           DMARD therapy to placebo plus DMARD therapy.

        -  Evaluate the efficacy of CRx-102 plus DMARD therapy to placebo plus DMARD therapy using
           ACR-20 and DAS28 indices as well as fatigue scales.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in CRP From Baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>The primary efficacy variable in this study was the change in CRP from Baseline (Day 1/Visit 2) to End of Study (Day 42/Visit 5). Blood samples for the analysis of serum CRP were taken at each visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of ACR 20 Scores at End of Study (Day 42/Visit 5)</measure>
    <time_frame>Day 42</time_frame>
    <description>The percentage of subjects in each group that achieved an ACR 20 response on Day 42</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28 Score From Baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>To calculate the DAS28, the number of swollen joints and tender joints should be assessed using 28-joint counts, the ESR should have been measured in mm/hour, and the patient's general health (GH) or global disease activity measured on a Visual Analog Scale (VAS) of 100 mm must be obtained. Using these data, the DAS28 could be calculated using the following formula: DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH. The DAS28 provides a number between 0 and 10 that indicates the current activity of RA in the subject. A DAS28 above 5.1 means high disease activity and below 3.2 indicates low activity. Remission is achieved when a DAS28 score is lower than 2.6. The DAS28 measurements were to be taken at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fatigue (MAF Scale) Score From Baseline to Day 42</measure>
    <time_frame>Baseline and Day 42</time_frame>
    <description>The Multidimensional Assessment of Fatigue (MAF) scale is a self-administered, 16 item questionnaire to measure self-reported fatigue (http://www.son.washington.edu/research/maf/). The following steps were used to calculate a single score ranging from 1 (no fatigue) to 50 (severe fatigue).
Convert item #15 to a 0 to 10 scale by multiplying each score by 2.5
Sum items #1, 2, and 3
Average items #4 through 14
Add results from above Steps 1 through 3 to obtain a single score
A score was not be assigned to items #4 through 14 if a respondent indicated they &quot;did not engage any activity for reasons other than fatigue.&quot; If respondent selected &quot;no fatigue&quot; on item #1, a 0 was to be assigned to items #2 through 16; item #16 was not included in the global fatigue index.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CRx-102 plus DMARD therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus DMARD therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRx-102</intervention_name>
    <arm_group_label>CRx-102 plus DMARD therapy</arm_group_label>
    <other_name>Prednisolone plus dipyridamole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo plus DMARD therapy</arm_group_label>
    <other_name>sugar pill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DMARD Therapy</intervention_name>
    <description>DMARD therapy can include methotrexate or other DMARD therapy</description>
    <arm_group_label>CRx-102 plus DMARD therapy</arm_group_label>
    <arm_group_label>Placebo plus DMARD therapy</arm_group_label>
    <other_name>Disease modifying anti-rheumatic drug therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Was 18 years of age of older

          -  Had moderate to severe RA

          -  Had at least 3 swollen joints (maximum 28) and 3 tender joints (maximum 28)

          -  Had a Baseline CRP level of at least 2.2 mg/L and a DAS28 score &gt;4.5

          -  Had been on DMARD therapy for at least 3 months and have been on a stable dose of
             DMARD therapy for at least 28 days prior to enrollment

          -  Had a negative pregnancy test (females)

          -  Was not taking glucocorticoids at screening

        Exclusion Criteria:

          -  Female subject is pregnant or lactating or of child bearing potential not using
             acceptable methods of birth control (barriers or abstinence). Female subjects using
             hormonal birth control are not to be enrolled.

          -  Subject is currently taking any steroids (glucocorticoids). All glucocorticoids must
             be discontinued for at least one month prior to entering study. Intraarticular,
             intramuscular, or intravenous glucocorticoids must not have been given at least 6
             weeks prior to entering the study.

          -  Subject is currently taking more than 81 mg of aspirin daily.

          -  Subject is currently taking a statin, unless she/he has been on a stable dose of the
             same statin for at least 3 months prior to entering into the trial.

          -  Subject has any active infections or recent surgical procedures within 30 days of
             study initiation.

          -  Subject has uncontrolled diabetes mellitus as defined by a HbA1C value ≥ 7.0%.

          -  Subject knowingly has HIV or Hepatitis.

          -  Subject has undergone administration of any investigational drug within 30 days of
             study initiation.

          -  Subject has a history of hypersensitivity to steroids and/or dipyridamole.

          -  Subject has limited mental capacity or language skills such that simple instructions
             cannot be followed or information regarding adverse events cannot be provided.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Lee, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Zalicus</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2008</study_first_submitted>
  <study_first_submitted_qc>September 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2008</study_first_posted>
  <results_first_submitted>January 16, 2014</results_first_submitted>
  <results_first_submitted_qc>April 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2014</results_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>RA</keyword>
  <keyword>DMARD</keyword>
  <keyword>CRP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antirheumatic Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CRx-102 Plus DMARD Therapy</title>
          <description>Daily oral treatment with CRx-102, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy
The following dose escalation scheme was used:
Days 1 to 7 Dose level 1: CRx-102 (200 mg dipyridamole + 3 mg prednisolone)
Days 8 to 42 Dose level 2: CRx-102 (400 mg dipyridamole + 3 mg prednisolone)</description>
        </group>
        <group group_id="P2">
          <title>Placebo Plus DMARD Therapy</title>
          <description>Daily oral treatment with placebo, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline analysis population is equal to the per protocol population defined as the subset of intent to treat population with no major protocol deviations including entry criteria and use of restricted medications and with study drug compliance of at least 75% during Days 1 to 42.</population>
      <group_list>
        <group group_id="B1">
          <title>CRx-102 Plus DMARD Therapy</title>
          <description>Daily oral treatment with CRx-102, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy
The following dose escalation scheme was used:
Days 1 to 7 Dose level 1: CRx-102 (200 mg dipyridamole + 3 mg prednisolone) Days 8 to 42 Dose level 2: CRx-102 (400 mg dipyridamole + 3 mg prednisolone)</description>
        </group>
        <group group_id="B2">
          <title>Placebo Plus DMARD Therapy</title>
          <description>Daily oral treatment with placebo, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.5" spread="6.53"/>
                    <measurement group_id="B2" value="60.0" spread="12.25"/>
                    <measurement group_id="B3" value="58.5" spread="10.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in CRP From Baseline to Day 42</title>
        <description>The primary efficacy variable in this study was the change in CRP from Baseline (Day 1/Visit 2) to End of Study (Day 42/Visit 5). Blood samples for the analysis of serum CRP were taken at each visit.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRx-102 Plus DMARD Therapy</title>
            <description>Daily oral treatment with CRx-102, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy
The following dose escalation scheme was used:
Days 1 to 7 Dose level 1: CRx-102 (200 mg dipyridamole + 3 mg prednisolone) Days 8 to 42 Dose level 2: CRx-102 (400 mg dipyridamole + 3 mg prednisolone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus DMARD Therapy</title>
            <description>Daily oral treatment with placebo, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CRP From Baseline to Day 42</title>
          <description>The primary efficacy variable in this study was the change in CRP from Baseline (Day 1/Visit 2) to End of Study (Day 42/Visit 5). Blood samples for the analysis of serum CRP were taken at each visit.</description>
          <units>percentage change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.12" spread="94.99"/>
                    <measurement group_id="O2" value="9.60" spread="74.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement of ACR 20 Scores at End of Study (Day 42/Visit 5)</title>
        <description>The percentage of subjects in each group that achieved an ACR 20 response on Day 42</description>
        <time_frame>Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRx-102 Plus DMARD Therapy</title>
            <description>Daily oral treatment with CRx-102, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy
The following dose escalation scheme was used:
Days 1 to 7 Dose level 1: CRx-102 (200 mg dipyridamole + 3 mg prednisolone) Days 8 to 42 Dose level 2: CRx-102 (400 mg dipyridamole + 3 mg prednisolone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus DMARD Therapy</title>
            <description>Daily oral treatment with placebo, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement of ACR 20 Scores at End of Study (Day 42/Visit 5)</title>
          <description>The percentage of subjects in each group that achieved an ACR 20 response on Day 42</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in DAS28 Score From Baseline to Day 42</title>
        <description>To calculate the DAS28, the number of swollen joints and tender joints should be assessed using 28-joint counts, the ESR should have been measured in mm/hour, and the patient's general health (GH) or global disease activity measured on a Visual Analog Scale (VAS) of 100 mm must be obtained. Using these data, the DAS28 could be calculated using the following formula: DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH. The DAS28 provides a number between 0 and 10 that indicates the current activity of RA in the subject. A DAS28 above 5.1 means high disease activity and below 3.2 indicates low activity. Remission is achieved when a DAS28 score is lower than 2.6. The DAS28 measurements were to be taken at each visit.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRx-102 Plus DMARD Therapy</title>
            <description>Daily oral treatment with CRx-102, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy
The following dose escalation scheme was used:
Days 1 to 7 Dose level 1: CRx-102 (200 mg dipyridamole + 3 mg prednisolone) Days 8 to 42 Dose level 2: CRx-102 (400 mg dipyridamole + 3 mg prednisolone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus DMARD Therapy</title>
            <description>Daily oral treatment with placebo, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in DAS28 Score From Baseline to Day 42</title>
          <description>To calculate the DAS28, the number of swollen joints and tender joints should be assessed using 28-joint counts, the ESR should have been measured in mm/hour, and the patient's general health (GH) or global disease activity measured on a Visual Analog Scale (VAS) of 100 mm must be obtained. Using these data, the DAS28 could be calculated using the following formula: DAS28 = 0.56 * sqrt(tender28) + 0.28 * sqrt(swollen28) + 0.70 * ln(ESR) + 0.014 * GH. The DAS28 provides a number between 0 and 10 that indicates the current activity of RA in the subject. A DAS28 above 5.1 means high disease activity and below 3.2 indicates low activity. Remission is achieved when a DAS28 score is lower than 2.6. The DAS28 measurements were to be taken at each visit.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.521" spread="1.574"/>
                    <measurement group_id="O2" value="-0.697" spread="1.435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fatigue (MAF Scale) Score From Baseline to Day 42</title>
        <description>The Multidimensional Assessment of Fatigue (MAF) scale is a self-administered, 16 item questionnaire to measure self-reported fatigue (http://www.son.washington.edu/research/maf/). The following steps were used to calculate a single score ranging from 1 (no fatigue) to 50 (severe fatigue).
Convert item #15 to a 0 to 10 scale by multiplying each score by 2.5
Sum items #1, 2, and 3
Average items #4 through 14
Add results from above Steps 1 through 3 to obtain a single score
A score was not be assigned to items #4 through 14 if a respondent indicated they &quot;did not engage any activity for reasons other than fatigue.&quot; If respondent selected “no fatigue” on item #1, a 0 was to be assigned to items #2 through 16; item #16 was not included in the global fatigue index.</description>
        <time_frame>Baseline and Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CRx-102 Plus DMARD Therapy</title>
            <description>Daily oral treatment with CRx-102, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy
The following dose escalation scheme was used:
Days 1 to 7 Dose level 1: CRx-102 (200 mg dipyridamole + 3 mg prednisolone) Days 8 to 42 Dose level 2: CRx-102 (400 mg dipyridamole + 3 mg prednisolone)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Plus DMARD Therapy</title>
            <description>Daily oral treatment with placebo, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fatigue (MAF Scale) Score From Baseline to Day 42</title>
          <description>The Multidimensional Assessment of Fatigue (MAF) scale is a self-administered, 16 item questionnaire to measure self-reported fatigue (http://www.son.washington.edu/research/maf/). The following steps were used to calculate a single score ranging from 1 (no fatigue) to 50 (severe fatigue).
Convert item #15 to a 0 to 10 scale by multiplying each score by 2.5
Sum items #1, 2, and 3
Average items #4 through 14
Add results from above Steps 1 through 3 to obtain a single score
A score was not be assigned to items #4 through 14 if a respondent indicated they &quot;did not engage any activity for reasons other than fatigue.&quot; If respondent selected “no fatigue” on item #1, a 0 was to be assigned to items #2 through 16; item #16 was not included in the global fatigue index.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.840" spread="10.605"/>
                    <measurement group_id="O2" value="-2.965" spread="9.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks: from screening (visit 1) up to 14 days prior to baseline (visit 2) through end of study (visit 5) on day 42.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CRx-102 Plus DMARD Therapy</title>
          <description>Daily oral treatment with CRx-102, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy
The following dose escalation scheme was used:
Days 1 to 7 Dose level 1: CRx-102 (200 mg dipyridamole + 3 mg prednisolone) or placebo equivalent Days 8 to 42 Dose level 2: CRx-102 (400 mg dipyridamole + 3 mg prednisolone) or placebo equivalent</description>
        </group>
        <group group_id="E2">
          <title>Placebo Plus DMARD Therapy</title>
          <description>Daily oral treatment with placebo, dosed twice per day (8AM and 1 PM) plus stable dose of DMARD therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>femoral hernia</sub_title>
                <description>Left femoral hernia that required hospitalization and surgical correction. In the opinion of the investigator this event was not related to study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Margaret Lee, PhD</name_or_title>
      <organization>Zalicus</organization>
      <phone>617-301-7142</phone>
      <email>mlee@zalicus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

